Stocktoria
CSPC Pharmaceutical Group Limited 1093.HK
HK · Hong Kong Stock Exchange · XHKG · stock · Healthcare · website
CSPC Pharmaceutical Group Limited financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | CN¥26.0B | CN¥29.0B | CN¥31.5B | CN¥30.9B |
| Gross profit | CN¥17.1B | CN¥20.3B | CN¥22.2B | CN¥22.3B |
| R&D expense | CN¥5.8B | CN¥5.2B | CN¥4.8B | CN¥4.0B |
| SG&A expense | CN¥7.3B | CN¥9.7B | CN¥10.3B | CN¥11.5B |
| Operating income | CN¥4.2B | CN¥5.5B | CN¥7.0B | CN¥6.8B |
| Interest expense | CN¥38.6M | CN¥43.7M | CN¥25.9M | CN¥24.9M |
| Income tax | CN¥931.7M | CN¥1.2B | CN¥1.3B | CN¥1.4B |
| Net income | CN¥3.9B | CN¥4.3B | CN¥5.9B | CN¥6.1B |
| EPS (diluted) | CN¥0.34 | CN¥0.37 | CN¥0.49 | CN¥0.51 |
| Operating cash flow | CN¥5.8B | CN¥4.5B | CN¥4.2B | CN¥7.6B |
| Free cash flow | CN¥3.6B | CN¥1.9B | CN¥2.3B | CN¥4.9B |
| Cash & equivalents | CN¥6.1B | CN¥6.8B | CN¥12.0B | CN¥10.3B |
| Inventory | CN¥3.1B | CN¥3.1B | CN¥3.1B | CN¥2.6B |
| Goodwill | CN¥234.9M | CN¥234.9M | CN¥234.9M | CN¥234.9M |
| Total assets | CN¥46.7B | CN¥44.4B | CN¥46.3B | CN¥41.8B |
| Total debt | CN¥641.1M | CN¥507.3M | CN¥706.9M | CN¥582.5M |
| Total liabilities | CN¥12.1B | CN¥10.5B | CN¥11.3B | CN¥10.1B |
| Shareholders' equity | CN¥33.2B | CN¥32.3B | CN¥33.2B | CN¥30.2B |
| Share buybacks | CN¥277.6M | CN¥1.6B | CN¥200.4M | CN¥14.2M |
Growth · year-over-year · Revenue CAGR -5.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | -10.4% | -7.8% | +1.7% | — |
| Net income growth | -10.3% | -26.3% | -3.6% | — |
| EPS growth | -7.8% | -25.5% | -3.2% | — |
| Free cash flow growth | +91.4% | -18.8% | -53.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · HK · as of 2025-12-31. Figures in CNY. Facts plus Stocktoria's own computed scores — not investment advice.